Profile data is unavailable for this security.
About the company
Perseus Proteomics Inc is a Japan-based company principally engaged in the research, development, manufacture and sale of pharmaceuticals. The Company is involved in the research and development of therapeutic drugs for cancer and other diseases and related businesses. The Company is involved in the research, development, licensing, and manufacturing method establishment for commercialization in the fields of drug discovery, antibody research support, as well as antibody and reagent sales. The products include PPMX-T001, a therapeutic agent that targets glypican 3 (GPC3) present on the surface of cancer cell membranes; PPMX-T002, a therapeutic agent that targets cadherin 3 (CDH3) present on the surface of cancer cells; PPMX-T003, a therapeutic agent that targets the transferrin receptor (TfR); PPMX-T004 therapeutic agent targeting cadherin 3 (CDH3) and others.
- Revenue in JPY (TTM)96.22m
- Net income in JPY-1.12bn
- Incorporated2001
- Employees24.00
- LocationPerseus Proteomics IncPark Bldg., 4-7-6, KomabaCHUO-KU 103-0015JapanJPN
- Phone+81 362648268
- Fax+81 336687776
- Websitehttps://www.ppmx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Modalis Therapeutics Corp | 0.00 | -2.39bn | 2.91bn | 37.00 | -- | 1.91 | -- | -- | -76.74 | -76.74 | 0.00 | 41.39 | 0.00 | -- | -- | 0.00 | -92.78 | -29.19 | -99.33 | -30.02 | -- | -- | -- | -597.35 | 9.84 | -- | 0.2301 | -- | -100.00 | -- | 11.50 | -- | 135.50 | -- |
| Atect Corp | 3.20bn | 114.29m | 3.00bn | 96.00 | 26.19 | 1.43 | 6.52 | 0.9388 | 25.85 | 25.85 | 723.76 | 474.92 | 0.5713 | 3.22 | 6.85 | 33,330,020.00 | 2.04 | 2.03 | 2.83 | 2.78 | 44.68 | 47.69 | 3.57 | 3.84 | 0.7119 | -- | 0.546 | 29.40 | -4.03 | 2.10 | -6.37 | 14.01 | -23.31 | 0.00 |
| Muromachi Chemicals Inc | 6.12bn | 216.69m | 3.03bn | 205.00 | 13.84 | 1.40 | 8.63 | 0.4951 | 53.45 | 53.45 | 1,503.34 | 527.87 | 1.20 | 3.83 | 3.75 | 29,862,370.00 | 4.23 | -- | 6.84 | -- | 28.31 | -- | 3.54 | -- | 1.45 | 26.20 | 0.4483 | -- | 10.74 | -- | -43.83 | -- | -- | -- |
| Ribomic Inc | 62.64m | -979.09m | 3.12bn | 25.00 | -- | 0.8566 | -- | 49.86 | -27.45 | -27.45 | 1.76 | 100.39 | 0.0144 | -- | 1.22 | 2,505,440.00 | -22.56 | -32.10 | -24.05 | -33.30 | -- | -- | -1,563.14 | -1,688.50 | 18.53 | -- | 0.00 | -- | -18.47 | 0.3809 | 1.88 | -- | 10.04 | -- |
| D.Western Therapeutics Institute Inc | 428.36m | -812.41m | 3.53bn | 21.00 | -- | 2.76 | -- | 8.25 | -25.45 | -25.45 | 13.48 | 39.83 | 0.1607 | 0.4389 | 2.98 | 20,398,290.00 | -31.09 | -13.06 | -33.75 | -14.36 | 91.44 | 94.29 | -193.39 | -72.51 | 10.57 | -- | 0.4089 | -- | -4.40 | 7.90 | -89.07 | -- | 7.08 | -- |
| Kringle Pharma Inc | 70.58m | -865.79m | 3.72bn | 13.00 | -- | 1.53 | -- | 52.67 | -158.59 | -158.59 | 12.88 | 374.93 | 0.024 | -- | 0.7308 | 5,428,846.00 | -29.38 | -19.00 | -30.70 | -20.23 | -- | -- | -1,226.76 | -156.51 | 26.45 | -1,190.33 | 0.00 | -- | -82.33 | -- | -157.41 | -- | -- | -- |
| Human Metabolome Technologies Inc | 1.32bn | 282.64m | 3.82bn | 57.00 | 13.49 | 2.16 | 10.46 | 2.89 | 47.83 | 47.83 | 223.67 | 299.17 | 0.6302 | 14.23 | 4.74 | 23,186,330.00 | 13.48 | -- | 16.73 | -- | 65.03 | -- | 21.39 | -- | 4.27 | 151.90 | 0.1103 | -- | 6.21 | -- | 6.71 | -- | -- | -- |
| FunPep Co Ltd | 530.00k | -933.42m | 3.82bn | 15.00 | -- | 1.55 | -- | 7,213.76 | -40.11 | -40.11 | 0.0225 | 94.97 | 0.0002 | -- | -- | 35,333.33 | -34.04 | -27.10 | -35.68 | -28.75 | -- | -- | -176,116.20 | -815.82 | 25.95 | -1,765.73 | 0.00 | -- | -50.33 | -72.80 | 20.39 | -- | -13.14 | -- |
| Kubota Pharmaceutical Holdings Co Ltd | 39.89m | -1.49bn | 4.00bn | 12.00 | -- | 1.50 | -- | 100.21 | -26.80 | -26.80 | 0.7175 | 47.21 | 0.0107 | 0.5317 | 14.77 | 3,323,917.00 | -40.06 | -36.51 | -43.86 | -39.47 | 70.48 | -- | -3,734.55 | -13,528.87 | 10.01 | -- | 0.0512 | -- | 383.24 | -- | 26.11 | -- | 24.38 | -- |
| OncoTherapy Science, Inc. | 901.22m | -1.19bn | 4.00bn | 60.00 | -- | 5.97 | -- | 4.44 | -5.77 | -5.77 | 4.36 | 3.01 | 0.7589 | 5.31 | 15.74 | 15,020,330.00 | -100.44 | -50.21 | -132.58 | -55.41 | -9.03 | -- | -132.35 | -331.97 | 3.29 | -258.18 | 0.00 | -- | -1.63 | 39.97 | 56.50 | -- | -57.92 | -- |
| Perseus Proteomics Inc | 96.22m | -1.12bn | 4.05bn | 24.00 | -- | 2.53 | -- | 42.09 | -95.57 | -95.57 | 8.18 | 131.49 | 0.0424 | 1.82 | 11.22 | 4,009,083.00 | -49.52 | -33.51 | -51.65 | -34.95 | 89.01 | 93.09 | -1,168.66 | -470.63 | 17.58 | -- | 0.00 | -- | 30.96 | -20.89 | -31.38 | -- | 228.18 | -- |
| BrightPath Biotherapeutics Co Ltd | 118.00k | -1.21bn | 4.22bn | 32.00 | -- | 5.03 | -- | 35,774.55 | -19.27 | -19.27 | 0.0019 | 11.92 | 0.00007 | -- | 0.0423 | 3,687.50 | -71.34 | -42.65 | -89.42 | -44.49 | -433.05 | 57.16 | -1,028,827.00 | -4,430.66 | -- | -875.45 | 0.3929 | -- | -65.73 | -56.89 | -0.0971 | -- | -56.39 | -- |
| Immuno-Biological Laboratories Co., Ltd. | 788.12m | -192.71m | 4.28bn | 60.00 | -- | 3.90 | -- | 5.44 | -20.69 | -20.69 | 84.62 | 118.02 | 0.5144 | 0.8788 | 3.78 | 13,135,280.00 | -12.58 | -15.11 | -14.85 | -17.61 | 62.06 | 56.66 | -24.45 | -50.04 | 3.49 | 0.494 | 0.1774 | -- | 22.71 | 0.9405 | -11.97 | -- | -- | -- |
| Renascience Inc | 191.32m | -331.66m | 4.44bn | 3.00 | -- | 2.70 | -- | 23.19 | -26.09 | -26.09 | 15.05 | 129.22 | 0.0851 | -- | -- | 63,772,000.00 | -14.74 | -- | -15.49 | -- | 85.75 | -- | -173.36 | -- | -- | -- | 0.1782 | -- | -27.84 | -- | -32.05 | -- | -- | -- |
| MEDRx Co Ltd | 29.53m | -932.90m | 4.60bn | 22.00 | -- | 2.25 | -- | 155.89 | -27.24 | -27.24 | 0.8492 | 50.17 | 0.0171 | 0.2606 | 1.22 | 1,342,455.00 | -54.07 | -58.15 | -58.45 | -62.23 | 91.87 | 95.70 | -3,158.72 | -1,526.17 | 17.75 | -- | 0.00 | -- | -50.35 | 28.60 | 16.04 | -- | -55.29 | -- |
| Solasia Pharma KK | 617.00m | -1.11bn | 5.18bn | 24.00 | -- | 2.50 | -- | 8.40 | -6.61 | -6.61 | 3.67 | 10.78 | 0.2301 | 4.10 | 1.93 | 25,708,330.00 | -41.51 | -48.57 | -47.74 | -58.83 | 54.78 | 71.01 | -180.39 | -300.89 | 2.91 | -- | 0.031 | -- | -43.50 | 14.18 | 56.36 | -- | -- | -- |
Data as of May 02 2024. Currency figures normalised to Perseus Proteomics Inc's reporting currency: Japanese Yen JPY
0.53%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nikko Asset Management Co., Ltd.as of 27 Sep 2022 | 62.40k | 0.53% |
| JPMorgan Asset Management (Japan) Ltd.as of 12 Sep 2022 | 0.00 | 0.00% |
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
